Members of the Cornell Health Policy Insight Panel had mixed views on whether greater use of reference pricing would lower ...

The way to bring down the political temperature is to invest in the one sector where the return may be larger than the ...

Each of the several bipartisan bills being considered by Congress to promote biosimilar competition would have major ...

Rob Lott and Irene Papanicolas examine how Americans pay for health care through taxes, premiums, and out-of-pocket costs, ...

Value-based care is conventionally classified as an alternative payment model. That classification mistakes the output for ...

After a series of losses in constitutional challenges to the Medicare Drug Price Negotiation Program, the drug industry seems to be moving to challenging the program on statutory grounds.

In the early parallel years, hybrid rates ran 6.2 percentage points above digital-only rates in commercial plans and 9.3 ...

Six pending federal bills would regulate private equity in health care, from an outright ban to disclosure, licensing, and antitrust tools. Rather than a categorical ban, federal policy makers could ...

From regulatory efforts to streamline approvals to emerging AI-driven decision-making, this episode explores the forces ...

This post examines the unique role of discrimination as a stressor and the part it plays in creating health inequities. Distinct from beliefs and stereotypes, discrimination refers to an action or ...

In their 2026 legislative sessions, state policymakers considered and enacted a wide variety of bills to improve affordability and strengthen their health care markets.

Medicare has created multiple opportunities to ask about fall risk. It has not created a dependable pathway to ensure that the answer changes care.